MENS Jyong Biotech Ltd.
NEUTRAL
Impact: 2/10
PRESS-RELEASE
Press release: earnings
Latest settled — T+5d
MENS ▲ +6.97% at T+5d
NEUTRAL call ✓ call won +6.97% · α vs SPY +6.00% · entry $2.01 → $2.15
Last close $2.00 (close Jun 8) · -0.50% from $2.01 entry
T+1d
-2.99%
call -2.99% · α -2.92%
$1.95
settled 23d ago
T+5d
+6.97%
call +6.97% · α +6.00%
$2.15
settled 19d ago
T+20d
—
call — · α —
—
in 5d
T+60d
—
call — · α —
—
in 2mo
Price Chart
Loading chart...
Executive Summary
Jyong Biotech filed its FY2025 annual report on Form 20-F, a routine regulatory milestone. The press release contains no financial results, guidance, or material business updates — it is purely an administrative filing notification.
Actionable Insight
This filing is purely procedural — no trading signal. Monitor for future clinical trial results or regulatory updates on BOTRESO® for potential catalysts.
Key Facts
- Filed FY2025 annual report on Form 20-F with the SEC on May 14, 2026
- No financial results, earnings, or guidance disclosed in the press release
- Company is a pre-commercialization biotech focused on plant-derived therapeutics for urinary system diseases
- Lead candidate BOTRESO® is in clinical development; no revenue reported
Financial Impact
No financial data disclosed — filing is administrative only
Risk Factors
- No revenue or near-term commercialization timeline disclosed
- Clinical-stage biotech with binary pipeline risk
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3295834 |
2 reports for MENS
Track record builds as more directional reports settle.
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 15, 2026
25d ago
|
Press Release
| $2.01 $2.15 | ▲ +6.97% | ▲ +6.00% | $2.00 (−0.50%) |
|
May 15, 2026
26d ago
|
20-F
| $2.01 $2.15 | ▼ −6.97% | ▼ −6.00% | $2.00 (+0.50%) |
Showing 2 of 2
US Market Status
Market Closed — Opens in 7h 15m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access